|Day Low/High||264.35 / 270.37|
|52 Wk Low/High||223.25 / 468.55|
These recently downgraded names are displaying both quantitative and technical deterioration.
RMPIA for the September-ending quarter is up .2%, outperforming most of the major market indexes. Let's dig in.
And It comes after one of the best days of the year for the biotech sector.
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
The stock market's rise might have ended after the cliff, not before it.
Small-caps and mid-caps are still picking first downs on every play, storming back from a badly oversold condition that has just about normalized.
This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.
Odd mix of moves precedes one of the most important Fed meetings in a while.
BioXcel Therapeutics and Albiero Pharma have promising prospects based on drugs in their pipelines.
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Traders who went long BIIB on our April recommendation should continue to hold those shares.
The drugmaker's charts are pointing to higher ground for its shares as a regulatory decision on its Alzheimer's drug aducanumab is at hand.
Canada made the developed world's first moves toward normalizing monetary policy coming out of the pandemic, despite the fact that Canada does not seem to be flattening its own curve.
Right off the top, the bubble has burst for the 'short squeeze' names such as GameStop and AMC Entertainment.
The RMPIA easily outpaced the main indexes for 2020, but slipped 1.7% last month.
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
The RMPIA also tops other indexes for year, shooting ahead 29%.
These names are displaying both technical and quantitative deterioration.
The average declined in October, but it was less than that hit took by the major indexes.
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
This is the type of chart that will grab the attention of momentum traders.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.